Enzalutamide and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Enzalutamide (enzalutamide), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Docetaxel, and have Prostate cancer.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Enzalutamide. It is created by eHealthMe based on reports of 14,017 people who have side effects when taking Enzalutamide from the FDA, and is updated regularly.

What is Enzalutamide?

Enzalutamide has active ingredients of enzalutamide. eHealthMe is studying from 14,018 Enzalutamide users. Check the latest studies of Enzalutamide.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,066 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

14,017 people reported to have side effects when taking Enzalutamide.
Among them, 33 people (0.24%) have Neoplasm progression.

Could Enzalutamide cause Neoplasm progression?

Among these 33 people:

How long have people been on Enzalutamide when they have Neoplasm progression? *

What is the gender of people who have Neoplasm progression when taking Enzalutamide? *

female: 0.0 %
male: 100 %

What is the age of people who have Neoplasm progression when taking Enzalutamide? *

What are other drugs people take besides Enzalutamide? *

What are other side effects people have besides Neoplasm progression? *

Abdominal Pain: 8 people, 24.24%
Pancreatitis (inflammation of pancreas): 8 people, 24.24%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 8 people, 24.24%
Death: 4 people, 12.12%
Anaemia (lack of blood): 3 people, 9.09%
Renal Impairment (severely reduced kidney function): 3 people, 9.09%
Prostatic Specific Antigen Increased: 2 people, 6.06%
Pneumonia: 2 people, 6.06%
Osteonecrosis Of Jaw (death of bone of jaw): 2 people, 6.06%
Osteitis (a general term for inflammation of bone): 2 people, 6.06%

What are the existing conditions these people have? *

Prostate Cancer: 20 people, 60.61%
Abdominal Pain: 8 people, 24.24%
Prostate Cancer Metastatic: 5 people, 15.15%
High Blood Pressure: 4 people, 12.12%
Pain: 2 people, 6.06%
Urination - Painful: 2 people, 6.06%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 6.06%
High Blood Cholesterol: 1 person, 3.03%
Cancer Pain: 1 person, 3.03%
Cardiac Failure: 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Enzalutamide and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Enzalutamide:

Enzalutamide (14,018 reports)

Browse all side effects of Enzalutamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,067 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enzalutamide (the active ingredients of Enzalutamide) and Enzalutamide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.